James McGee, MD
Internal Medicine · Paris, TNNPI 1053407890
Payments from drug & device makers
Across 83 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$170
- Novo Nordisk$145
- Takeda Pharmaceuticals U.S.A., Inc.$139
- Merck$125
- Exact Sciences$93
- Dexcom, Inc.$69
- plus $684 from 19 others
What the payments were for
- Food & beverage$1,33694%
- Education$453%
- Gifts$463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 8 | $170 |
| Novo Nordisk | 8 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
| Merck | 16 | $125 |
| Exact Sciences | 4 | $93 |
| Dexcom, Inc. | 4 | $69 |
| Pfizer | 3 | $64 |
| Johnson & Johnson | 4 | $59 |
| Bayer | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Abbott | 2 | $49 |
| Sanofi Pasteur Inc. | 1 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Amgen | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $41 |
| AstraZeneca | 2 | $40 |
| GSK | 2 | $30 |
| Mylan Specialty L.p. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Axonics, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| AbbVie | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $12 |
How this compares
$1,427 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 155 | $178,460 |
| EliquisApixaban | 216 | $154,054 |
| JanuviaSitagliptin Phosphate | 92 | $61,349 |
| JardianceEmpagliflozin | 58 | $47,843 |
| OzempicSemaglutide | 32 | $37,760 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $29,502 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $28,578 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $22,473 |
| Risperdal ConstaRisperidone Microspheres | 15 | $21,395 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $17,151 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,372 |
| XareltoRivaroxaban | 20 | $13,255 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 250 | $12,556 |
| FarxigaDapagliflozin Propanediol | 18 | $12,368 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $170 | $178,460155 claims |
| PfizerEliquis | $64 | $154,054216 claims |
| MerckJanuvia, Janumet, Janumet Xr | $125 | $84,950128 claims |
| Boehringer IngelheimJardiance | $25 | $47,84358 claims |
| Novo NordiskOzempic | $145 | $37,76032 claims |
| Johnson & JohnsonRisperdal Consta, Xarelto | $59 | $34,65035 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $30 | $32,14854 claims |
| AstraZenecaFarxiga, Symbicort | $40 | $14,88029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Paris
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.